Video decision support tool promoting values conversations in advanced care planning in cancer: protocol of a randomised controlled trial

Natasha Michael1,2,3*, Clare O’Callaghan1,4, Ekavi Georgousopoulou2, Adelaide Melia1, Merlina Sulistio1,2,3 and David Kissane1,2,3

Abstract

Background: Views on advance care planning (ACP) has shifted from a focus solely on treatment decisions at the end-of-life and medically orientated advanced directives to encouraging conversations on personal values and life goals, patient-caregiver communication and decision making, and family preparation. This study will evaluate the potential utility of a video decision support tool (VDST) that models values-based ACP discussions between cancer patients and their nominated caregivers to enable patients and families to achieve shared-decisions when completing ACP’s.

Methods: This open-label, parallel-arm, phase II randomised control trial will recruit cancer patient-caregiver dyads across a large health network. Previously used written vignettes will be converted to video vignettes using the recommended methodology. Participants will be 18 years and be able to complete questionnaires. Dyads will be randomised in a 1:1 ratio to a usual care (UC) or VDST group. The VDST group will watch a video of several patient-caregiver dyads communicating personal values across different cancer trajectory stages and will receive verbal and written ACP information. The UC group will receive verbal and written ACP information. Patient and caregiver data will be collected individually via an anonymous questionnaire developed for the study, pre and post the UC and VDST intervention.

Our primary outcome will be ACP completion rates. Secondly, we will compare patient-caregiver (i) attitudes towards ACP, (ii) congruence in communication, and (iii) preparation for decision-making.

Conclusion: We need to continue to explore innovative ways to engage cancer patients in ACP. This study will be the first VDST study to attempt to integrate values-based conversations into an ACP intervention. This pilot study’s findings will assist with further refinement of the VDST and planning for a future multisite study.

Trial registration: Australian New Zealand Clinical Trials Registry No: ACTRN12620001035910. Registered 12 October 2020. Retrospectively registered.

Keywords: Advance care planning, Cancer, Communication, End-of-life care, Complex intervention, Decision aid

* Correspondence: nmichael@cabrini.com.au
1Supportive, Psychosocial and Palliative Care Research Department, Cabrini Health, Melbourne, VIC, Australia
2School of Medicine, Sydney Campus, University of Notre Dame Australia, Darlington, Darlinghurst, NSW, Australia
Full list of author information is available at the end of the article

© The Author(s) 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background

All people have the right to make decisions about how they are cared for in the future. However, many lose this ability as they approach the end-of-life (EOL). Advance care planning (ACP) may provide an avenue to ascertain patients’ wishes in circumstances where they are unable to articulate them due to a loss of capacity [1, 2]. A recent multidisciplinary panel of ACP experts defined ACP “as a process that supports adults at any age or stage of health in understanding and sharing their personal values, life goals, and preferences regarding future medical care” [3]. Elucidating ACP enhances desirable EOL outcomes, including patient-caregiver confidence and satisfaction [4, 5], quality of death [2, 6], and family bereavement experiences [6]. ACP requires reflection and communication and is an iterative process that is both individualized and shared [7, 8]. Contemporary views have shifted from ACP focused solely on treatment decisions at the EOL and medically orientated advanced directives. It instead encourages conversations that communicate personal values and life goals to support patient-caregiver communication and decision-making [9], family preparation [10, 11], and the actualization of ACP’s through innovative interventions [12].

Specific ACP challenges are recognized in cancer care, with ACP in cancer limited in completion, scope, timing, and translation into desired care [13]. Patients commonly prefer discussions later in their cancer journey [14], initiated by their treating physicians, and prefer multiple opportunities for conversations [13, 15]. The physician is required to strike a balance between engendering hope and maintaining truthful communication that ideally incorporates prognostic information [16]. Low uptake may be associated with standardized programs failing to capture the complex social and emotional nuances experienced by the cancer patient and their family across ages, genders, cancer types, and trajectories [17].

Cancer is a family experience, and the heightened involvement of family caregivers in cancer ACP studies is welcomed [10, 18]. Fluctuating awareness of treatment goals among cancer patients and their primary caregivers and the lack of concordance in patient-caregiver communication in cancer impacts effective care [19, 20]. However, cancer care provision in the ambulatory setting has augmented the opportunity to align patient-caregiver communication to support patient-caregiver dynamics, coping, adjustment, and psychological well-being [21]. Patients’ and caregivers’ assertive behaviours alongside caregiver presence in cancer consultations can reinforce patients’ participation in care discussions. This then allows for the triadic alignment of goals between the patient, caregiver, and health professionals [22, 23]. Such opportunities may then allow us to explore how individual and shared family values may influence treatment decision-making.

ACP interventions involving cancer patients on the whole, have increased ACP documentation rates from 15 to 30%–40% but failed to achieve EOL care consistent with patients’ preferences [24]. It is increasingly accepted that patient’s values and beliefs are the best predictors of the choices they make relating to end of life goals and treatment decisions [25], leading to ACP research exploring EOL values and the development of values-based ACP documents [26, 27]. Incorporating values directives into ACP removes the emphasis of decisions on specific medical interventions, such as cardiopulmonary resuscitation and intubation. It allows a focus on questions related to personal and family relationships, future concerns related to health, spiritual care, and end of life contingency planning [26]. In maturing the research around EOL values, tools such as decision aids with designs responsive to diverse philosophical perspectives are needed, with the flexibility to change as patients gain experience with their personal illness course.

Video decision aids or Video Decision Support Tools (VDST) incorporating video vignettes in ACP are garnering considerable interest amongst academics, clinicians, and policymakers due to their ability to dynamically depict diminishing health states and the nature of different treatment options in culturally and ethically congruent manners. A recent systematic review and meta-analysis of 10 randomised controlled trial’s (RCT’s) (2220 patients) examining VDST to assist ACP found that patients who use a VDST were less likely to indicate a preference for cardiopulmonary resuscitation (pooled RR, 0.50; 95% CI 0.27–0.95) and acquired improved ACP knowledge [12]. Only four trials reported data on completion of advance directives, with no studies examining the effect on improved preparation in decision-making or patient-caregiver communication.

This study aims to build on the paucity of research exploring conversations about individual values between cancer patient-caregiver dyads and examining their impact on EOL decision-making and ACP. We hypothesize that patients exposed to a VDST that models values-based ACP discussions between patient-caregiver dyads can be an innovative approach to promote ACP in cancer. This study aims to evaluate the effect of a VDST depicting values communication on rates of completion of ACP, attitudes towards ACP, congruence in communication and preparedness for decision-making. The protocol is outlined according to the SPIRIT (Standard Protocol Items: Recommendations for Intervventional Trials) guidelines [28].
Methods / design

Study design and setting

This is a prospective, RCT with two parallel groups receiving usual care (UC) or VDST intervention forms part of a research program of ACP in cancer developed in accordance with the Medical Research Council framework for developing complex interventions [29]. In this exploratory study, participants are enrolled in the study as dyads – a patient diagnosed with incurable cancer and a nominated caregiver. In this study, caregivers are defined as a relative, partner, or friend who has a significant relationship with the patient and provides them with social, psychological, and physical assistance [30].

The study will be conducted across three sites in a large not-for-profit health network Melbourne, Australia. ACP in the hospital is governed by legislation through a jurisdictional Medical Treatment Planning and Decision Act 2016 [31]. The Act establishes a single framework for medical treatment decision-making for people without decision-making capacity that ensures that people receive medical treatment consistent with their preferences and values. Standard forms under the Act allow for the appointment of a Medical Treatment Decision Maker (MTDM) and Support Person and completion of a Values and Instructional Directive (Table 1).

Participants and recruitment

Patients with non-curable cancer will be recruited from the oncology and palliative care across different sites at the health network. Eligible patients will have a diagnosis of incurable cancer and not have completed current ACP documents. Patients who have previously only appointed a MEPOA will be eligible to participate. Both patients and caregivers will have to be over the age of 18, be sufficiently proficient in English, and have a clinically determined prognosis of a minimum of 8 weeks post-randomization. Patients and caregivers will be ineligible for the trial if they are deemed too unwell and are unable to give informed consent due to cognitive or language barriers.

Development of video vignettes

The video vignettes will be developed from the findings of our preliminary research into ACP in cancer patients [7, 10]. These studies incorporated the use of written vignettes, depicting a cancer patient’s scenarios across four stages of the cancer trajectory. In our preliminary studies, patients were depicted as declining in function and requiring various levels of care [7, 10, 32, 33]. Vignettes were presented to patients and caregivers in interviews and focus groups to elicit views on ACP and subsequently to patient-caregiver dyads as part of a facilitator-guided intervention in a feasibility study [32]. Qualitative secondary analysis on the use of written vignettes revealed that the vignettes provide a platform to promote values-based conversations and may facilitate congruence in communication between the patient and caregiver [33].

In developing the video vignettes, the research team will adhere to suggested guidelines for the preparation

| Table 1 Components of an advance care plan/directive |
|---------------------------------|-------------------------------------------------|
| Appointment of Medical Treatment Decision Makers and Support Persons |
| Medical Treatment Decision Maker* | A medical treatment decision maker has the legal authority to make medical treatment decisions on behalf of the patient if they do not have the decision-making capacity to make a decision. It is the first person the patient listed who is reasonably available, and willing and able to make a decision. Only adults can appoint a medical treatment decision maker. |
| Support Person | A support person can access, or help a patient access health information relevant to their medical treatment. The support person does not have the power to make medical treatment decisions on the patient’s behalf. |
| Medical Enduring Power of Attorney | A medical enduring power of attorney authorizes another person to make decisions about medical care and treatment on a patient’s behalf if they do not have the decision-making capacity to make a decision. The person making the medical enduring power of attorney is called the appointer, and the person who accepts the appointment is the agent. |
| Values and Instructional Directives |
| Values Directive | A medical treatment decision maker is legally required first to consider the patient’s values directive when making decisions about their medical treatment. |
| Instructional Directive | An instructional directive is legally binding and communicates the patients’ medical treatment decision(s) directly to their health practitioner(s). It is recommended that the patient consult a medical practitioner if they choose to complete an instructional directive. |
| – An instructional directive will only be used if the patient does not have the decision-making capacity to make a medical treatment decision. |
| – The medical treatment decisions in the instructional directive take effect as if the patient has consented to, or refused to, begin or continue medical treatment. |
| – If any of the statements in an Instructional Directive are unclear or uncertain in particular circumstances, it will become a values directive. |
| – In some limited circumstances set out in the Act, a health practitioner may not be required to comply with an instructional directive. |
| – The patient has the option of consenting to or refusing future medical treatment. |

*The appointment of a MTDM replaced the appointment of a Medical Enduring Power of Attorney (MEPOA). A MEPOA appointment made before the law changed is recognized under the new Act.
of scripted video vignettes which are 1) deciding on the appropriateness of the use of video vignettes, 2) developing a valid script, 3) designing valid manipulations, 4) converting written scripts to video, 5) administering the videos [34].

The written script will be developed by senior clinicians, drawing from cases used in previous studies [7, 10]. Manipulations will include representation of patient-caregiver dyads from differing ages, gender, stages of illness and relationships e.g. older patient and spouse/partner; middle-aged patient and sibling; younger patient and friends). This, as well as settings and furnishing, will be selected to enhance the participant’s perception of reality [34]. The video vignettes will depict dyads scenarios communicating across three stages of a cancer trajectory, with each stage introducing considerations for completion of different sections of an ACP (Table 2). Professional actors will be sourced from known professional college and university sources, and a pilot video will be created before the filming of the final videos. The video vignettes will be circulated to a multidisciplinary team for validation and approval and further editing before the final video intervention is created.

Study procedures
The study procedure is shown in Fig. 1. Participating clinicians will screen patients for eligibility, and interested eligible patients will be asked to nominate a participating caregiver. Eligible dyads will be informed verbally and in writing about the study and will be invited to meet with a research facilitator in their own homes or an allocated room in the hospital at an assigned date and time.

Patients and caregivers will be consented individually by the research facilitator and will complete individual baseline pre-questionnaires (Supplementary file). Participants will then be randomised as dyads to either the UC or VDST arm. All participants will be advised that participation is voluntary, they may withdraw at any time, and that all information gathered will be treated in the strictest confidence. Patients and caregivers will also be advised that non-participation will not affect their care or their choice to complete an ACP.

Patients from both groups will be advised to discuss their completed ACP with their general practitioner or treating specialist to clarify any questions. The completed ACP will have to be signed, witnessed and returned with the post-questionnaire in a stamped return envelope. Participants will be advised to return the questionnaires even if they choose not to complete the ACP. Participants will receive two telephone call prompts at two-week intervals on completion of the intervention as a reminder to return the completed documents. Returned ACP’s will be scanned into the hospital’s electronic record system, and a copy returned to the patient.

Sample size and power
Based on the primary outcome of the completion of ACP documentation and assuming a completion rate of around 37% for the control group, with a total of 86 participants/dyads (43 per group) we will be able to show a significant improvement to 67% completion for the VDST group (power of 80%, two sided 5% significance level). Assuming an estimated dropout rate of 30%, recruitment of 112 dyads will be required. Based on previous published studies, we felt that a sample of this size would give us sufficient methodological experience to conduct a subsequent fully powered study [12].

Quality standards
Randomization and blinding
Randomization occurs after completion of baseline assessments. An independent randomization administrator will complete randomization at the individual level using a computer-generated random number sequence in blocks of 6 in 1:1 ratio and with concealed allocation using numbered envelopes. The nature of the intervention makes it impossible to blind study participants. Treatment group assignments will therefore be non-blinded, but outcome assessors will be blinded to allocation.

Table 2 Predicted scenarios depicted in the video decision support tool

| Vignette | Cancer stage | Values conversation depicted | ACP outcomes encouraged |
|----------|--------------|------------------------------|-------------------------|
| Vignette 1 Early cancer diagnosis | Early diagnosis, good performance status | Active treatment to preserve life at any cost | Appointment of a Medical Treatment Decision Maker and Support Person |
| Vignette 2 Living with serious illness | Progressive metastatic disease, deteriorating performance status | Sustaining a reasonable quality of life through illness. Reflection of values and reprioritization of life choices | Completion of Values Directive. Consider when to discontinue cancer treatments / accept or refuse treatments based on acceptable quality of life |
| Vignette 3 Approaching the end of life | Advanced metastatic disease, increased dependence | Effects of progressive frailty on quality of life despite active treatment. Reflection of meaningful relationships and EOL values | Completion of Instructional Directive. Discuss cardiopulmonary resuscitation, invasive/life-prolonging interventions, preferred place of death, contingencies e.g. funeral plans, spiritual needs. |
Fig. 1 Study procedure

- Patients screened for eligibility
- Eligible patients to nominate caregivers who meet eligibility criteria
- Dyads consent and complete baseline assessment individually
- Dyads Randomisation 1:1
- Usual Care Group (N=43)
  - Dyads provided with
    - explanation of ACP
    - ACP document and guidelines on how to complete an ACP
    - Post intervention questionnaires to be completed individually
  - Completed ACP discussed with GP/Specialist, signed, witnessed and returned with completed questionnaires*
  - Returned ACP document scanned into hospital electronic medical record system, copy to patient and G Practitioner
- VDST Group (N=43)
  - Dyads provided with
    - explanation of ACP
    - ACP document and guidelines on how to complete an ACP
    - Post intervention questionnaires to be completed individually
  - Completed ACP discussed with GP/Specialist, signed, witnessed and returned with completed questionnaires*
  - Returned ACP document scanned into hospital electronic medical record system, copy to patient and G Practitioner
- Data analysis of ACP document and completed questionnaire

*Participants advised to return questionnaires even if they choose not to complete ACP
Facilitator training and distress management
Research facilitators will be trained in ACP principles and familiarised with recent changes to legislation with the introduction of the Medical Treatment Planning and Decision Act 2016 [31]. They will additionally be familiarised with ACP and the specificities of the appointment of an MTDM and completion of Instructional and Values Directives. Given that the video vignettes may potentially elicit distress in participants, research facilitators will also be trained on how to respond to distress and procedures around seeking additional support for participants. Researchers will be advised to offer to discontinue the video if deemed appropriate.

Data monitoring and confidentiality
Research facilitators will be asked to complete field notes as part of the study monitoring plan. The project team will meet monthly to review the progress of the study. Adherence to the research protocol will be monitored throughout the study. Protocol violations or operational issues will be discussed and resolved at project team meetings. The study steering committee will monitor the study and provide ongoing oversight into early results. If necessary, modifications to the study will be made. To ensure confidentiality, data will be stored in a secure database. Information and measurements will be stored independently from identifiable personal information.

Study arms
Usual care
Patient-caregiver dyads will be provided with a verbal explanation of ACP, an ACP document, and verbal and written guidelines on how to complete the document. Questions will be fielded, and finally, participants will be provided with the patient and caregiver post-questionnaires to be completed individually and returned with the completed ACP in a stamped return envelope.

VDST group
Participants randomised to the VDST group will be shown the video on a mobile computer. The video will be viewed by patient-caregiver dyads simultaneously. Research facilitators will offer to discontinue the video at any point if it elicits distress. Following this, the participants will be provided with a verbal explanation of ACP and be provided with the hospital’s ACP document, and verbal and written guidelines on how to complete the document. Questions will be fielded, and finally, participants will be provided with patient and caregiver post-questionnaires to be completed individually and returned with the completed ACP in a stamped return envelope.

Outcome assessment
The primary outcome measure will be the completion of ACP documentation. We will specifically examine the completion of various sections of the ACP (Appointment of MTDM and Support Person, Values and Instructional Directives). The following secondary outcomes that will be assessed will be attitudes towards ACP, congruence in communication and preparedness for decision-making.

Data collected and measures used
Table 3 outlines the measures used at baseline and post-intervention. The baseline questionnaire will include the patient’s and caregiver’s demographic information, including age, sex, marital status, place of birth, the relationship between patient and caregiver, primary cancer diagnosis, and length of time living with the diagnosis. Patients will be asked if they had previously discussed prognosis with their doctor.

The following variables and outcomes will be assessed:

1. Baseline Depression, Anxiety and Stress scores. The DASS 21 scale is a validated 21 item self-reported questionnaire designed to measure the negative emotional states of depression, anxiety, and stress [35]. Evaluation of the DASS 21 in cancer has shown acceptable internal consistency reliability for the Depression subscale (α = .90) and Anxiety subscale (α = .70) with construct validity to measures of suicidal ideation, quality of life, self-rated health, and depressed mood [36].

| Measures used | Patient | Caregiver |
|---------------|---------|-----------|
|               | Baseline: Pre UC/VDST | Post UC/VDST | Baseline: Pre UC/VDST | Post-UC/VDST |
| Demographics  | x       |           | x                     |              |
| DASS-21       | x       |           | x                     |              |
| ACP Attitudes | x       | x         | x                     | x            |
| CCAT          | x       | x         | x                     | x            |
| PDMS          | x       | x         | x                     | x            |

DASS-21 Depression, Anxiety and Stress Scale, CCAT Cancer Communication and Assessment Tool, PDMS Preparation for Decision Making Scale.
2. **Attitudes towards ACP.** Understanding of, opportunities, distress, and confidence related to ACP will be assessed using a previously designed and tested questionnaire comprising nine patient and eight caregiver items, measured on a 10 point Likert scale [32].

3. **Congruence in decision-making** will be measured using the Cancer Communication Assessment Tool for Patients and Families (CCAT-PF). CCAT-PF consists of 18 items and measures congruence in patient-caregiver communication with the analogous patient (CCAT-P) and family (CCAT-F) instruments, exploring preferences, values, and experiences in treatment decision-making. The CCAT-PF demonstrated internal reliability coefficients for the CCAT-P ($\alpha = .52$), CCAT-F ($\alpha = .50$), and CCAT-PF ($\alpha = .60$). Higher CCAT-PF scores are significantly correlated with greater patient depression and perceived family conflict, lower patient-caregiver assessment and well-being, and less expressiveness and family cohesion [37].

4. **Preparation for decision-making** will be measured using the Preparation for decision-making scale, a validated scale assessing patient and caregiver perception of an intervention’s usefulness. Psychometric analysis has shown Alpha coefficients for internal consistency ranging from 0.92 to 0.96 and that the scale discriminated significantly between patients who did and did not find a decision aid helpful ($p < 0.0001$) [38].

**Statistical analysis**

Descriptive statistics will be presented as frequencies and relative frequencies for categorical variables, mean and standard deviation for normally distributed continuous variables, or median and interquartile range for continuous variables that are not normally distributed. We will examine secondary outcomes between the two groups comparing pre and pre and post-test intervention changes with Chi-square or Fisher’s exact test for categorical variables and two-sample t-tests or Mann-Whitney test for continuous variables. Additionally, multiple linear regression will be performed, addressing the effect of socio-demographic and clinical variables to explore factors associated with the rates of completion of ACP. All results obtained will be presented at a confidence interval of 95%. Thus $p < 0.05$ is assumed to be statistically significant. The statistical software SPSS 23 will be used in this analysis.

**Discussion**

We present the protocol for a pilot randomised control trial developed as part of a body of work exploring ACP in cancer in the Australian setting. This study follows from previous studies conducted by members of the research team, demonstrating the feasibility and acceptability of the written vignette technique, recruitment of patient-caregiver dyads, and completion of ACP’s. The use of video vignettes as a decision aid is supported by a Cochrane review of 115 RCTs involving 34,444 participants showing that compared to UC, decision aids improve knowledge, accurate risk perception, likelihood of selecting options congruent with personal values, and reduce decisional conflict [39]. The video vignette technique has been proven to be acceptable and effective in several North American settings and, it is possible that this equally effective in the Australian setting [12].

A novel aspect of this study is the use of video vignettes to promote values discussion. The use of video to explore a values-based ACP paradigm has been shown to be successful in a single study [40]. This approach’s potential benefit in increasing the uptake of ACP in cancer care may allow for more meaningful EOL care planning between patients and their families. Our use of patient-caregiver dyads is relatively unique to ACP video intervention studies. This is despite evidence that suggests the benefit of congruence in communication between patient and caregiver, particularly in the cancer setting [22].

**Limitations**

There remains a paucity of literature on the methodological challenges that may arise with video vignettes’ development. Even the most realistic scripted video vignettes may differ from communication as it naturally unfolds. It is suggested that the manipulation of less defined concepts such as ‘the communication of values’ in our study through video vignettes poses specific challenges due to challenges in operationalizing such concepts.

Intervention studies in cancer cohorts typically demonstrate significant attrition rates due to progressive illness and high mortality [41]. Cancer patients also not uncommonly remain ambivalent or choose to relinquish or reject ACP as they potentially elicit death anxiety or other existential distress forms. Finally, this study provides an intervention at a single time point, is restricted to a single site and will not measure subsequent congruence between documented ACP decisions and EOL outcomes. It also limits recruitment to English-speaking participants with no provision made for those with limited health literacy and cannot participate.

**Conclusion**

We need to continue to explore innovative ways to engage cancer patients in ACP. This pilot study’s findings will assist with further refinement of the VDST and planning for a future multisite study.
Abbreviations
ACP: Advance care planning; CCAT: Cancer Communication Assessment Tool; CCAT-P: Cancer Communication Assessment Tool for Patient; CCAT-F: Cancer Communication Assessment Tool for Families; MTPA: Medical Treatment Decision Maker; UC: Usual care; VDST: Video decision support tool

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12904-021-00794-3.

Acknowledgements
We thank Nerida Morton and Genevieve Murphy for their assistance with this study.

Authors' contributions
NM conceived the study, developed the study protocol with COC and DK, drafted the manuscript, and is the study coordinator. MS and AM provided leadership in participant recruitment. EG designed the statistical analysis plan. All authors approved the final version of the manuscript.

Funding
This work was supported by the Cabrini Foundation Medical Oncology Research Grant and the Bethlehem Griffith Research Foundation Grant (no 1709). The funding bodies had no involvement in the design of the study, data collection, analysis and interpretation or writing of the manuscript.

Availability of data and materials
Not applicable as the manuscript does not contain data from any individual person.

Declarations
Ethics approval and consent to participate
The study protocol was approved by the Monash Health Research Ethics Committee (Reference Number: RES-20-0000-112C). Participants will only be enrolled into the study if they provide written informed consent.

Consent for publication
Not applicable as the manuscript does not contain data from any individual person.

Competing interests
The authors declare that they have no competing interests.

Author details
1Supportive, Psychosocial and Palliative Care Research Department, Cabrini Health, Melbourne, VIC, Australia. 2School of Medicine, Sydney Campus, University of Notre Dame Australia Darlinghurst, Darlinghurst, NSW, Australia. 3Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, VIC, Australia. 4Departments of Psychosocial Cancer Care, St Vincent’s Hospital, Sydney, NSW, Australia.

Received: 27 October 2020 Accepted: 10 June 2021

Published online: 24 June 2021

References
1. Rietjens JA, Sudore RL, Connolly M, van Delden JJ, Drickamer MA, Droger M, et al. Definition and recommendations for advance care planning: an international consensus supported by the European Association for Palliative Care. Lancet Oncol. 2017 Sep 1;18(9):e543–51. https://doi.org/10.1016/S1470-2245(17)30582-X.

2. Fleuren N, Depla MFIA, Janssen DJA, Huisman M, Hertogh CM. Underlying goals of advance care planning (ACP): a qualitative analysis of the literature. BMC Palliat Care. 2020;19(1):27. https://doi.org/10.1186/s12904-020-00535-1.

3. Sudore RL, Lum HD, You J, Hanson LC, Meier DE, Pantilat SZ, et al. Defining advance care planning for adults: a consensus definition from a multidisciplinary delphi panel. J Pain Symptom Manag. 2017;53(9):821–32. https://doi.org/10.1016/j.jpainsymman.2016.12.331.

4. Bravo G, Sene M, Arcand M, Hérault E. Effects of advance care planning on confidence in surrogates’ ability to make healthcare decisions consistent with older adults’ wishes: findings from a randomised controlled trial. Patient Educ Couns. 2018;101(7):1256–61. https://doi.org/10.1016/j.pec.2018.02.005.

5. Jimenez G, Tan WS, Vik AK, Low CK, Car J, Ho AH. Overview of systematic reviews of advance care planning: summary of evidence and global lessons. J Pain Symptom Manag. 2018;56(3):436–59. https://doi.org/10.1016/j.jpainsymman.2018.05.016.

6. Brinkman-Stoppelenburg A, Rietjens JA, van der Heide A. The effects of advance care planning on end-of-life care: a systematic review. Palliat Med. 2014;28(8):1000–25. https://doi.org/10.1177/269213451452277.

7. Michael N, O’Callaghan C, Clayton J, Pollard A, Stepanov N, Spruyt O. Understanding how cancer patients actualize, relinquish, and reject advance care planning: implications for practice. Support Care Cancer. 2013;21(8):2195–205. https://doi.org/10.1007/s00520-013-1779-4.

8. Fried TR, Redding CA, Robbins ML, Paiva A, O’Leary JR, Iannone LN. Promoting advance care planning as health behavior change: development of scales to assess decisional balance, medical and religious beliefs, and processes of change. Patient Educ Couns. 2012;86(1):125–32. https://doi.org/10.1016/j.pedecare.2011.04.035.

9. Sudore RL, Heyland DK, Lum HD, Rietjens JA, Korfage IJ, Ritchie CS, et al. Outcomes that define successful advance care planning: A Delphi panel Consensus. J Pain Symptom Manag. 2018;55(2):245–55. https://doi.org/10.1016/j.jpainsymman.2017.08.025.

10. Michael N, O’Callaghan C, Baird A, Hiscock N, Clayton J. Cancer caregivers advocate a patient- and family-centered approach to advance care planning. J Pain Symptom Manag. 2014;47(6):1064–77. https://doi.org/10.1016/j.jpainsymman.2013.07.009.

11. Fried T, Zenoni M, Iannone L. A dyadic perspective on engagement in advance care planning. J Am Geriatr Soc. 2017;65(1):172–8. https://doi.org/10.10111/jgs.14497.

12. Jain A, Coriveaux S, Quinn K, Gardhouse A, Vestag DB, You JI. Video decision aids to assist with advance care planning: a systematic review and meta-analysis. BMJ Open. 2015;5(6):e007491. https://doi.org/10.1136/bmjopen-2014-007491.

13. Dow LA, Matsuyma RK, Ramakrishnan V, Kuhn L, Lamont EB, Lyckholm L, et al. Paradoxes in advance care planning: the complex relationship of oncology patients, their physicians, and advance medical directives. J Clin Oncol. 2010;28(2):299–304. https://doi.org/10.1200/JCO.2009.24.6397.

14. Barnes KA, Barlow CA, Harrington J, Ornadel K, Tookman A, King M, et al. Advance care planning discussions in advanced cancer: analysis of dialogues between patients and care planning mediators. Palliat Support Care. 2013;11(1):73–9. https://doi.org/10.1017/S147895151000568.

15. Alkuwaila SC, Levin JR, Lorenz KA, Gordon HS. Missed opportunities for advance care planning communication during outpatient clinic visits. J Gen Intern Med. 2012;27(4):445–51. https://doi.org/10.1007/s11606-011-1917-0.

16. Chu C, Anderson R, White N, Stone P. Prognosticating for adult patients with advanced incurable cancer: a needed oncologist skill. Curr Treat Options in Oncol. 2020;21(1):5. https://doi.org/10.1007/s11864-019-0698-2.

17. Johnson S, Butow P, Kerridge I, Tattersall M. Advance care planning for cancer patients: a systematic review of perceptions and experiences of patients, families, and healthcare providers. Psycho-Oncology. 2016;25(4):362–86. https://doi.org/10.1002/pon.3926.

18. Costello J. The role of informal caregivers at the end of life: providing support through advance care planning. Int J Palliat Nurs. 2017;23(2):60–4. https://doi.org/10.12968/ijpn.2017.23.2.60.

19. Burns CM, Broom DH, Smith WT, Dear K, Craft PS. Fluctuating awareness of treatment goals among patients and their caregivers: a longitudinal study of a dynamic process. Support Care Cancer. 2007;15(2):187–96. https://doi.org/10.1007/s00520-006-0116-8.

20. Wen FH, Chou WC, Chen JS, Chang WC, Hsieh CH, Tang ST. Evolution and predictors of patient-caregiver concordance on states of life-sustaining treatment preferences over terminally ill cancer patients’ last
six months of life. J Palliat Med. 2019;22(1):25–33. https://doi.org/10.1089/jpm.2018.0307.

21. Waller A, Turon H, Bryant J, Zucca A, Evans TJ, Sanson-Fisher R. Medical oncology outpatients’ preferences and experiences with advanced care planning: a cross-sectional study. BMC Cancer. 2019;19(1):1–8. https://doi.org/10.1186/s12885-019-5272-6.

22. Laidaar-Powell R, Butow P, Bu S, Charles C, Gafni A, Lam WW, et al. Physician–patient–companion communication and decision-making: a systematic review of triadic medical consultations. Patient Educ Couns. 2013;91(1):3–13. https://doi.org/10.1016/j.pec.2012.11.007.

23. Post DM, Cegala DJ, Miser WF. The other half of the whole: teaching patients to communicate with physicians. Fam Med. 2002;34(5):344–52.

24. Bestvina CM, Polite BN. Implementation of advance care planning in oncology: a review of the literature. J Oncol Pract. 2017;13(10):657–62. https://doi.org/10.1200/JOP.2017.021246.

25. Winter L. Patient values and preferences for end-of-life treatments: are values better predictors than a living will? J Palliat Med. 2013;16(4):362–8. https://doi.org/10.1089/jpm.2013.0303.

26. Hoverman JR, Taniguchi C, Eagye KJ, Ash-Lee S, Kalisiak A, Mikan SQ, et al. Using a values assessment as a bridge to advance care planning: Results of 1286 patient reports. J Clin Oncol. 2016;34(26_suppl):12.

27. Epstein AS, Apos, Reilly EM, Roman D, Li Y, Breitbart W, et al. A randomized trial of acceptability and effects of values-based advance care planning in outpatient oncology: person-centered oncologic care and choices. J Pain Symptom Manag. 2018;56(2):169–77. https://doi.org/10.1016/j.jpainsymman.2018.04.009.

28. Chan AW, Teti L, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jurina K, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials, Ann Intern Med. 2013;158(3):200–7. https://doi.org/10.7326/M03-4819-158-3-201302050-00583.

29. Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M. Developing and evaluating complex interventions: the new Medical Research Council guidance. Bmj. 2008;337. https://doi.org/10.1136/bmj.a7655.

30. Hudson P, Payne S. The future of family caregiving: research social policy and clinical practice. In: Hudson P, Payne S, editors. Family carers in palliative care: a guide for health and social care professionals. Oxford: Oxford University Press; 2009. p. 277–303.

31. https://www2.health.vic.gov.au/hospitals-and-health-services/patient-care/end-of-life-care/advance-care-planning/medical-treatment-planning-and-decisions-act. Accessed July 2020.

32. Michael N, O’Callaghan C, Baird A, Gough K, Krishnasamy M, Hiscock N, et al. Patient values and preferences for end-of-life treatments: are values better predictors than a living will? J Palliat Med. 2013;16(4):362–8. https://doi.org/10.1089/jpm.2013.0303.

33. https://doi.org/10.1007/s12904-017-0519-9.

34. Hillen MA, van Vliet LM, de Haes HC, Smets EM. Developing and evaluating complex interventions: the new Medical Research Council guidance. Bmj. 2008;337. https://doi.org/10.1136/bmj.a7655.

35. Lovibond SH, Lovibond PF. Manual for the depression anxiety stress scales. 2nd ed. Sydney: Psychology Foundation; 1995.

36. Fox RS, Lillis TA, Gerhart J, Hoeger M, Duberstein P. Multiple group confirmatory factor analysis of the DASS-21 depression and anxiety scales: how do they perform in a cancer sample? Psychol Rep. 2017;121(3):548–65. https://doi.org/10.1177/0033294177277477.

37. Siminoe LF, Zysmansk SJ, Rose K, Zhang AY. The Cancer communication assessment tool for patients and families (CCAT-PF): a new measure. [published correction appears in psycho-oncology. 2016 Jun;25(8):883.] Psycho-Oncology. 2008;17(12):1216–24. https://doi.org/10.1002/pin.1350.

38. Bennett C, Graham ID, Kristjansson E, Kearing SA, Clay KF, O’Connor AM. Validation of a preparation for decision making scale. Patient Educ Couns. 2010;78(1):130–3. https://doi.org/10.1016/j.pec.2009.05.012.

39. Stacey D, Legare F, Lewis K, Barry MJ, Bennett CL, Eden KB, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2017;4:CD001431. https://doi.org/10.1002/14651858.CD001431.pub5.

40. Epstein AS, O’Reilly EM, Shuk E, Romano D, Li Y, Breitbart W, et al. A randomized trial of acceptability and effects of values-based advance care planning in outpatient oncology: person-centered oncologic care and choices. J Pain Symptom Manag. 2018;56(2):169–77. https://doi.org/10.1016/j.jpainsymman.2018.04.009.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.